Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

Autor: Leroux-Roels I; Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium., Koutsoukos M, Clement F, Steyaert S, Janssens M, Bourguignon P, Cohen K, Altfeld M, Vandepapelière P, Pedneault L, McNally L, Leroux-Roels G, Voss G
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2010 Oct 08; Vol. 28 (43), pp. 7016-24. Date of Electronic Publication: 2010 Aug 20.
DOI: 10.1016/j.vaccine.2010.08.035
Abstrakt: This randomized double-blind study aimed to determine the safety and immunogenicity of a gp120/NefTat candidate human immunodeficiency virus type 1 (HIV-1) vaccine formulated with one of three different Adjuvant Systems (AS02(A), AS02(V) and AS01(B)) in healthy HIV-seronegative adults. All vaccine formulations induced strong HIV-specific CD4(+) T-cell responses characterized by high lymphoproliferative capacity and IL-2 production that were still detectable 18 months after last immunization, with strongest responses seen in the AS01(B) group. Broad coverage was demonstrated against gp120, and to a lesser extent Nef, derived from the most common circulating clades (B, C and circulating recombinant form [CRF]-01). All vaccine formulations exhibited acceptable safety and reactogenicity profiles. The demonstration of superior CD4(+) T-cell induction by AS01(B) provides important guidance for future HIV vaccine development.
(Copyright © 2010. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: